aTyr Pharma Balance Sheet Health
Financial Health criteria checks 5/6
aTyr Pharma has a total shareholder equity of $65.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $91.6M and $26.5M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$65.99m |
| Equity | US$65.14m |
| Total liabilities | US$26.48m |
| Total assets | US$91.62m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 471A's short term assets ($76.3M) exceed its short term liabilities ($14.1M).
Long Term Liabilities: 471A's short term assets ($76.3M) exceed its long term liabilities ($12.4M).
Debt to Equity History and Analysis
Debt Level: 471A is debt free.
Reducing Debt: 471A has no debt compared to 5 years ago when its debt to equity ratio was 39.6%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 471A has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 471A has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 18.1% each year.